Online inquiry

IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2339MR)

This product GTTS-WQ2339MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 5-Methyl-CTP & Pseudo-UTP. It ecodes the monoclonal antibody that targets MS4A1 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP & Pseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001048028.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 485430
UniProt ID Q3C2E2
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MS4A1, AME-133v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2339MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ2187MR IVTScrip™ mRNA-Anti-IL15, ALT-803(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA ALT-803
GTTS-WQ11689MR IVTScrip™ mRNA-Anti-influenza B virus hemagglutinin, MHAB5553A(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MHAB5553A
GTTS-WQ12248MR IVTScrip™ mRNA-Anti-CD274, MPDL3280A(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA MPDL3280A
GTTS-WQ7184MR IVTScrip™ mRNA-Anti-CD19, FMC63 scFv-28Z CAR(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA FMC63 scFv-28Z CAR
GTTS-WQ14386MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ4359MR IVTScrip™ mRNA-Anti-B7, BMS-188667(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-188667
GTTS-WQ2101MR IVTScrip™ mRNA-Anti-IFNAR1&IFNAR2, Alb-IFNA2 R23 (608)(Cap 1, Pseudo-UTP, 30 nt-poly(A)) mRNA Alb-IFNA2 R23 (608)
GTTS-WQ14819MR IVTScrip™ mRNA-Anti-CD70, SGN-75(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA SGN-75
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW